Stock Watch: The Rise Of Biotech Platforms
Platform Derivatives Of Drug Development Have Lower Risks
In a wilderness period for biotech stocks, platform company revenues may offer investors less volatile biotech exposure. They are unlikely to shepherd an exit from the current doldrums, though.
